Phreesia (NYSE:PHR) Announces Earnings Results

Phreesia (NYSE:PHR) posted its quarterly earnings results on Monday. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.11, Zacks reports. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%.

Phreesia Price Performance

Shares of Phreesia stock traded down $0.01 during midday trading on Monday, hitting $20.28. 3,640,192 shares of the company were exchanged, compared to its average volume of 631,028. The firm has a 50 day simple moving average of $22.09 and a 200-day simple moving average of $25.28. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.12 and a quick ratio of 2.12. The firm has a market cap of $1.21 billion, a P/E ratio of -48.28 and a beta of 0.64. Phreesia has a 52 week low of $18.55 and a 52 week high of $32.76.

Insider Activity

In other Phreesia news, SVP Amy Beth Vanduyn sold 1,762 shares of Phreesia stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total transaction of $41,019.36. Following the completion of the transaction, the senior vice president directly owned 112,479 shares of the company’s stock, valued at approximately $2,618,511.12. This trade represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Evan Roberts sold 3,761 shares of the company’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total transaction of $87,556.08. Following the completion of the sale, the insider directly owned 726,837 shares in the company, valued at approximately $16,920,765.36. The trade was a 0.51% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 26,174 shares of company stock valued at $603,835. 5.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Phreesia

Large investors have recently bought and sold shares of the business. Royal Bank of Canada increased its holdings in Phreesia by 208.8% during the 1st quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock valued at $617,000 after purchasing an additional 16,309 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Phreesia by 471.2% during the first quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after purchasing an additional 132,015 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Phreesia by 3.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock valued at $1,599,000 after buying an additional 2,158 shares in the last quarter. NewEdge Advisors LLC raised its holdings in shares of Phreesia by 262.7% in the first quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock valued at $395,000 after buying an additional 11,181 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Phreesia by 0.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock worth $15,336,000 after buying an additional 2,402 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on PHR. Citigroup reissued an “outperform” rating on shares of Phreesia in a research report on Monday, September 8th. Piper Sandler lifted their price objective on Phreesia from $33.00 to $34.00 and gave the stock an “overweight” rating in a report on Friday, September 5th. BMO Capital Markets began coverage on Phreesia in a research report on Thursday, November 13th. They set an “outperform” rating and a $32.00 price objective on the stock. Mizuho started coverage on Phreesia in a research report on Wednesday, August 27th. They issued an “outperform” rating and a $36.00 target price for the company. Finally, Raymond James Financial set a $33.00 price target on shares of Phreesia and gave the stock an “outperform” rating in a research note on Friday, September 5th. Fourteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Phreesia presently has an average rating of “Moderate Buy” and an average price target of $33.86.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.